Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 4:46 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 1,570 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Metabolic and Nutritional Complications Clear all
Terminated No phase listed Observational Accepts healthy volunteers

Investigating the Relationship Between Triglycerides and Fetal Overgrowth in Gestational Diabetes

NCT06067685
View directory record Official record
Conditions
Fetal Macrosomia, Obesity Complicating Childbirth, Gestational Diabetes
Interventions
Observation
Other
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
Not listed
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 20, 2024 · Synced Oct 16, 2026, 4:46 AM EDT
Terminated Not applicable Interventional Results available

Closed Incision Negative Pressure Wound Therapy vs. Foam as Post Operative Dressing

NCT05427916
View directory record Official record
Conditions
Diabetes, Morbid Obesity, Lymphedema, Orthopedic Disorder
Interventions
Avance Solo, Optifoam
Device · Other
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 13, 2024 · Synced Oct 16, 2026, 4:46 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Tissue-Specific Metabolic Reprogramming in Diabetic Complications

NCT01823406
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Euglycemic clamp (normal blood sugar clamp) for 4 hours, hyperglycemic clamp (elevated blood sugar to 300) for 4 hours
Procedure
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 28, 2018 · Synced Oct 16, 2026, 4:46 AM EDT
Terminated Phase 2 Interventional Results available

A Ph2b to Evaluate Tildacerfont in the Reduction of Glucocorticoid Steroid Doses in Adult CAH

NCT04544410
View directory record Official record
Conditions
Congenital Adrenal Hyperplasia
Interventions
Tildacerfont/Placebo
Drug
Lead sponsor
Spruce Biosciences
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
18
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Oct 16, 2026, 4:46 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Suprachoroidal Injection of CLS-TA Alone or With Aflibercept in Subjects With Diabetic Macular Edema

NCT02949024
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
IVT Aflibercept, SC CLS-TA
Drug
Lead sponsor
Clearside Biomedical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Mountain View, California • The Woodlands, Texas
Source: ClinicalTrials.gov public record
Updated May 13, 2021 · Synced Oct 16, 2026, 4:46 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Program to Reduce Incontinence by Diet and Exercise

NCT00091988
View directory record Official record
Conditions
Urinary Incontinence
Interventions
Lifestyle & Behavioral Change Program, Structured Education Program
Behavioral
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
30 Years and older · Female only
Enrollment
338 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2007
U.S. locations
4
States / cities
Birmingham, Alabama • Little Rock, Arkansas • San Francisco, California + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2020 · Synced Oct 16, 2026, 4:46 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Gestational Diabetes Mellitus (GDM) in Pregnant Women

NCT05265741
View directory record Official record
Conditions
Gestational Diabetes Mellitus, Pregnancy Complications
Interventions
Not listed
Lead sponsor
Long Island University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 13, 2023 · Synced Oct 16, 2026, 4:46 AM EDT
Not yet recruiting Phase 4 Interventional

Role of Finerenone in African American Veterans With Diabetic Kidney Disease

NCT07155694
View directory record Official record
Conditions
Diabetic Kidney Disease
Interventions
Finerenone 10 MG, Empagliflozin 10 MG
Drug
Lead sponsor
Washington D.C. Veterans Affairs Medical Center
Federal
Eligibility
20 Years to 90 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 16, 2026, 4:46 AM EDT
Terminated Early Phase 1 Interventional

Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer

NCT04906382
View directory record Official record
Conditions
Lynch Syndrome, Recurrent Endometrial Carcinoma, Recurrent Endometrial Clear Cell Adenocarcinoma, Recurrent Uterine Corpus Carcinosarcoma, Mismatch Repair Deficiency, Recurrent Endometrial Cancer, Metastatic Endometrial Cancer
Interventions
Biopsy, Carboplatin, Paclitaxel, Tislelizumab
Procedure · Drug · Biological
Lead sponsor
Floor Backes, MD
Other
Eligibility
18 Years and older · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 13, 2025 · Synced Oct 16, 2026, 4:46 AM EDT
Not listed No phase listed Observational

OneinSeven Gestational Diabetes Genetic and Socioeconomic Risk Study

NCT04789473
View directory record Official record
Conditions
Gestational Diabetes, Pregnancy Complications, Pregnancy Related, Genetic Predisposition, Risk Reduction
Interventions
Polygenic Risk Score Generation
Genetic
Lead sponsor
Prenome
Industry
Eligibility
18 Years and older · Female only
Enrollment
10,000 participants
Timeline
2021 – 2022
U.S. locations
1
States / cities
Foster City, California
Source: ClinicalTrials.gov public record
Updated Jun 30, 2021 · Synced Oct 16, 2026, 4:46 AM EDT
Recruiting No phase listed Observational

Correlation Vitamin D Level to Endocrine Autoimmune Toxicity Due to Immune Checkpoint Inhibitors

NCT04615988
View directory record Official record
Conditions
Thyroid, PD-1, Cancer
Interventions
blood draw and questionnaire completion, questionnaire completion, blood collection
Other
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 16, 2026, 4:46 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3, Randomized, Double Blind, Placebo-Controlled, Multi-Center, Withdrawal Study of MCI-196 in CKD on Dialysis With Hyperphosphatemia

NCT00506441
View directory record Official record
Conditions
Chronic Kidney Disease, Dialysis, Hyperphosphatemia
Interventions
MCI-196, Placebo
Drug
Lead sponsor
Tanabe Pharma Corporation
Industry
Eligibility
18 Years and older
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
38
States / cities
Glendale, Arizona • Tempe, Arizona • Hot Springs, Arkansas + 35 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Oct 16, 2026, 4:46 AM EDT
Not listed Not applicable Interventional

Effect of Spironolactone on Adrenal or Ovarian Androgen Production in Overweight Pubertal Girls With Androgen Excess

NCT01422759
View directory record Official record
Conditions
Obesity, Hyperandrogenemia, Polycystic Ovary Syndrome
Interventions
Spironolactone
Drug
Lead sponsor
University of Virginia
Other
Eligibility
7 Years to 18 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 27, 2023 · Synced Oct 16, 2026, 4:46 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Transcutaneous Electrical Stimulation and Controlled Heat in People With and Without Diabetes

NCT07063524
View directory record Official record
Conditions
Diabetes, Heat, Perfusion; Complications
Interventions
Electrical stimulation
Device
Lead sponsor
Western Michigan University
Other
Eligibility
45 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Kalamazoo, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 14, 2025 · Synced Oct 16, 2026, 4:46 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Physical Activity and Community EmPOWERment Project

NCT06740162
View directory record Official record
Conditions
Intellectual Disability, Neurodevelopmental Disorders, Autism Spectrum Disorder, Down Syndrome, Fragile X Syndrome, Cri-du-Chat Syndrome, De Lange Syndrome, Mental Retardation, X-Linked, Prader-Willi Syndrome, Rubinstein-Taybi Syndrome, Trisomy 13 Syndrome, WAGR Syndrome, Williams Syndrome
Interventions
PACE Program
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
376 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
2
States / cities
Fayetteville, Arkansas • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Oct 16, 2026, 4:46 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Using Data From a Multisensor Rapid Health Assessment Device to Predict Decompensation in Long COVID (AIDI)

NCT05713266
View directory record Official record
Conditions
COVID-19, Long COVID
Interventions
MouthLabTM
Device
Lead sponsor
Edith Nourse Rogers Memorial Veterans Hospital
Federal
Eligibility
18 Years and older
Enrollment
204 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Bedford, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 16, 2024 · Synced Oct 16, 2026, 4:46 AM EDT
Enrolling by invitation Not applicable Interventional

Study to Understand Risk Information to Support and Empower

NCT05752292
View directory record Official record
Conditions
Diabetes, Gestational, Diabetes Mellitus, Type 2
Interventions
Standard Health Information, Values Affirmation (VA), Tailored Risk Information (TRI), Motivational Interviewing-based (MI), Action planning (AP)
Behavioral
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older · Female only
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Pleasanton, California
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 16, 2026, 4:46 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy

NCT02065791
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Diabetic Nephropathy
Interventions
Canagliflozin, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
30 Years and older
Enrollment
4,401 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
152
States / cities
Birmingham, Alabama • Montgomery, Alabama • Tempe, Arizona + 149 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2019 · Synced Oct 16, 2026, 4:46 AM EDT
Completed No phase listed Observational

User Testing and Feedback for a Mobile Health Program for Postpartum Women: A Pilot Study

NCT02384226
View directory record Official record
Conditions
Gestational Diabetes Mellitus, Preeclampsia, Gestational Hypertension, Pre-term Delivery, Delivery of Small for Gestational Age (SGA) Baby
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 25, 2022 · Synced Oct 16, 2026, 4:46 AM EDT
Terminated Phase 2 Interventional Results available

A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular Edema

NCT01994291
View directory record Official record
Conditions
Macular Edema, Diabetic
Interventions
Ranibizumab, Placebo, PF-04634817, Masked Sham Therapy
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
33
States / cities
Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2016 · Synced Oct 16, 2026, 4:46 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Oxabact in Patients With Primary Hyperoxaluria

NCT03116685
View directory record Official record
Conditions
Primary Hyperoxaluria
Interventions
Oxabact OC5 - Oxalobacter formigenes HC-1, Placebo
Biological · Other
Lead sponsor
OxThera
Industry
Eligibility
2 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 10, 2021 · Synced Oct 16, 2026, 4:46 AM EDT
Completed No phase listed Observational

miRNA in Fetal Overgrowth

NCT01935076
View directory record Official record
Conditions
Obesity
Interventions
Neonatal exposure to maternal obesity
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 26, 2014 · Synced Oct 16, 2026, 4:46 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Time Restricted Eating for the Treatment of PCOS

NCT05629858
View directory record Official record
Conditions
Polycystic Ovary Syndrome, Obesity, Overweight
Interventions
6-h Time restricted eating (TRE), Calorie restriction (CR), Control
Other
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 13, 2025 · Synced Oct 16, 2026, 4:46 AM EDT
Completed Phase 1 Interventional

Phase 1 Study of FG-3019 in Subjects With Type 1 or Type 2 Diabetes Mellitus and Diabetic Nephropathy

NCT00754143
View directory record Official record
Conditions
Diabetes Mellitus, Diabetic Nephropathy
Interventions
FG-3019
Drug
Lead sponsor
Kyntra Bio
Industry
Eligibility
18 Years to 80 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
18
States / cities
Birmingham, Alabama • Tempe, Arizona • La Mesa, California + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2019 · Synced Oct 16, 2026, 4:46 AM EDT